JA
John Adams
Chief Scientific OfficerDr. John Adams, Ph.D., is Chief Scientific Officer of Inhibikase Therapeutics, Inc. from February 2025. Dr. Adams joined the Inhibikase Therapeutics, Inc. in February 2025. He was Senior Vice President of Discovery Biology of Iambic Therapeutics, Inc. until 2024. He has joined Inhibikase from CorHepta where he was co-founder and Chief Scientific Officer. Previously he was Senior Vice President of Discovery Biology at Iambic Therapeutics, Senior Vice President of Translational Science at Reneo Pharmaceuticals and the Head of Research at Arena Pharmaceuticals. Dr. Adams earned his PhD in Physiological Science at UCLA and his B.S. Biological Sciences from U.C. Santa Barbara.
Positions
- Company NameInhibikase Therapeutics, Inc.Stock CodeIKTPositionChief Scientific OfficerColleagues
- MTMark T. IwickiCEO & Director
- ADAmit D. MunshiIndependent Chairman
- CHChristopher H. CabellPresident, Head of Research & Development and Chief Medical Officer
- DJDavid John McIntyreChief Financial Officer
- JJJeffrey J. KagyChief Human Resources Officer
- AKArvind KushIndependent Director
- RFRoberto Francesco BelliniIndependent Director
- TMTed M. DawsonMember of Scientific Advisory Board
